RNA-Sequencing Analysis of HepG2 Cells Treated with Atorvastatin by Stormo, Camilla et al.
RNA-Sequencing Analysis of HepG2 Cells Treated with
Atorvastatin
Camilla Stormo1*, Marianne K. Kringen2, Robert Lyle3, Ole Kristoffer Olstad1, Daniel Sachse4,
Jens P. Berg1,4, Armin P. Piehler5
1Department of Medical Biochemistry, Oslo University Hospital, Ulleva˚l, Oslo, Norway, 2Department of Pharmacology, Oslo University Hospital, Ulleva˚l, Oslo, Norway,
3Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway, 4 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo,
Oslo, Norway, 5 Fu¨rst Medical Laboratory, Oslo, Norway
Abstract
The cholesterol-lowering drug atorvastatin is among the most prescribed drug in the world. Alternative splicing in a number
of genes has been reported to be associated with variable statin response. RNA-seq has proven to be a powerful technique
for genome-wide splice variant analysis. In the present study, we sought to investigate atorvastatin responsive splice
variants in HepG2 cells using RNA-seq analysis to identify novel candidate genes implicated in cholesterol homeostasis and
in the statin response. HepG2 cells were treated with 10 mM atorvastatin for 24 hours. RNA-seq and exon array analyses
were performed. The validation of selected genes was performed using Taqman gene expression assays. RNA-seq analysis
identified 121 genes and 98 specific splice variants, of which four were minor splice variants to be differentially expressed,
11 were genes with potential changes in their splicing patterns (SYCP3, ZNF195, ZNF674, MYD88, WHSC1, KIF16B, ZNF92,
AGER, FCHO1, SLC6A12 and AKAP9), and one was a gene (RAP1GAP) with differential promoter usage. The IL21R transcript
was detected to be differentially expressed via RNA-seq and RT-qPCR, but not in the exon array. In conclusion, several novel
candidate genes that are affected by atorvastatin treatment were identified in this study. Further studies are needed to
determine the biological significance of the atorvastatin responsive splice variants that have been uniquely identified using
RNA-seq.
Citation: Stormo C, Kringen MK, Lyle R, Olstad OK, Sachse D, et al. (2014) RNA-Sequencing Analysis of HepG2 Cells Treated with Atorvastatin. PLoS ONE 9(8):
e105836. doi:10.1371/journal.pone.0105836
Editor: Ken Mills, Queen’s University Belfast, United Kingdom
Received May 28, 2013; Accepted July 30, 2014; Published August 25, 2014
Copyright:  2014 Stormo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the Division of Diagnostics and Intervention, Oslo University Hospital, Norway and by grants from The Blix Family Foundation
and Sigrid Wolmar Fund for Heart and Lung Diseases. The sequencing service was provided by the Norwegian Sequencing Centre (www.sequencing.uio.no) a
national technology platform supported by the Research Council of Norway and the Southeastern Regional Health Authorities. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Armin Piehler is a consultant in medical biochemstry at Fu¨rst Medical Laboratory. He has received lecturer fees from Siemens. He has no
competing interests to declare, and this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* Email: camilla.stormo@medisin.uio.no
Introduction
Atorvastatin is an efficient competitive inhibitor of 3-hydroxy-3-
methylglutaryl-Coenzyme A (HMG-CoA) reductase (HMGCR),
the rate-limiting enzyme in cholesterol synthesis. Atorvastatin
belongs to the statin class of drugs and is widely used to reduce
cholesterol levels and the risk of cardiovascular disease. The
cholesterol-lowering effect of statins is well documented. Statins
block HMGCR and prevent the conversion of HMG-CoA to
mevalonate and thereby decrease the level of sterol and non-sterol
products derived from mevalonate, including cholesterol. As a
compensatory effect, sterol-regulated genes, such as HMGCR and
low-density lipoprotein (LDL) receptor (LDLR), are upregulated to
increase de novo cholesterol synthesis and the receptor-mediated
uptake of LDL-cholesterol from the blood.
Statins are generally well tolerated in most people [1–3];
however, there is a large amount of variability in the responses
across individuals, which can be partly explained by genetic factors
[4]. Interestingly, the expression level of a minor splice variant of
HMGCR lacking exon 13 has been shown to be associated with
variations in the plasma LDL-cholesterol levels and statin response
[5]. Statins may also induce a range of adverse, muscle-related
events in 1–5% of patients [6]. In addition, beneficial effects of
statins on endothelial function, inflammation, and plaque stability
have been demonstrated, suggesting that statins have effects
beyond lowering cholesterol [7]. The exact molecular mechanisms
underlying these LDL-cholesterol independent effects of statins are
still unclear.
Studies on global gene expression effects of statin treatment
have mostly been performed by microarray analysis [8–13].
Microarrays have been used in gene expression studies for nearly
two decades, whereas RNA sequencing (RNA-seq) is a relatively
new approach for this purpose [14,15]. Briefly, RNA is converted
into cDNA, which is fragmented and PCR-amplified before being
subjected to parallel sequencing to generate millions of reads. The
gene expression and splice variant levels are determined using the
RNA-seq data by counting the number of sequence reads aligned
to each gene in the genome.
Human hepatoma HepG2 cells are considered a useful model
for studying the effects of statin treatment on hepatocytes [16–18].
Because alternative splicing has been reported to be relevant for
cholesterol homeostasis and variation in statin response in a
number of genes [5,19–23], we sought to investigate statin
responsive splice variant expression changes to identify novel
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candidate genes as potential regulators of the statin response. In
this study, we used RNA-seq in combination with microarray
analysis to provide a comprehensive transcriptome profile of
HepG2 cells exposed to atorvastatin.
Methods
Cell culture and treatment
The human hepatoblastoma cell line HepG2 (American Type
Culture Collection, Manassas, VA, USA) was maintained in
collagen I-coated tissue culture flasks (BD Biosciences, San Jose,
CA, USA) and modified Eagle’s minimal essential medium (MEM;
ATCC), supplemented with 10% heat inactivated fetal bovine
serum (FBS) and 1% penicillin-streptomycin-glutamine mixture
(Sigma-Aldrich, St Louis, MO, USA). In the treatment experi-
ments, cells were seeded at 26105 cells/mL in a 12-well collagen
I-coated plate (BD Biosciences). The following day, the medium
was changed to 1 mL growth medium containing 3 mg/mL of
human lipoprotein deficient serum (LPDS; Millipore, Billerica,
MA, USA) instead of FBS. Because we wanted to study the effects
of statin that were due to the inhibition of cholesterol biosynthesis,
we used the magnitude of increased HMGCR mRNA expression
as a marker for statin response. The initial experiments showed
that HepG2 cells grown in medium containing 10% FBS had low
HMGCR mRNA levels, which remained unchanged when treated
with atorvastatin. We therefore took advantage of LPDS to
activate cholesterol biosynthesis and increase the expression of
HMGCR in both the control and atorvastatin-treated cells, as
previously demonstrated [24]. In the dose response experiments,
cells were treated with water dissolved (3S, 5S)-atorvastatin sodium
salt (Toronto Research Chemicals North York, Ontario, Canada)
at various concentrations (0, 2.5, 5, 10, 20 and 40 mM) for
24 hours in four independent experiments. For RNA-seq and
exon array experiments, cells were treated with or without 10 mM
atorvastatin for 24 hours in triplicate wells.
RNA isolation
The cells were lysed by the addition of 700 mL QIAzol Lysis
Reagent. The phase separation was achieved by applying 2 mL of
Phase Lock Gel Heavy (5PRIME Inc., Gaithersburg, MD, USA)
to the lysates. RNA was then purified from the aqueous phase
using the miRNeasy Mini Kit (Qiagen, Venlo, The Netherlands),
according to the manufacturer’s instructions. The RNA was eluted
in 30 mL of RNase/DNase-free water and stored at 280uC until
analysis. The A260/A280 ratio and RNA concentration were
determined using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). The RNA
quality was assessed by microfluidic capillary electrophoresis using
an Agilent 2100 Bioanalyzer and the RNA 6000 Nano Chip kit
(Agilent Technologies, Santa Clara, CA, USA). An A260/A280
ratio in the range of 1.8 to 2.0 and an RIN.7 were considered
acceptable. RNA samples were denatured for 2 min at 70uC prior
to cDNA synthesis.
RNA-seq
Total RNA (500 ng) from each sample was prepared using
TruSeq RNA sample prep reagents (Illumina, San Diego, CA,
USA) according to manufacturer’s instructions, with fragmenta-
tion for 4 min at 94uC. The amplified fragmented cDNA of
,200 bp in size were sequenced in paired-end mode using the
HiSeq 2000 (Illumina) with a read length of 26100 bp. Two
FASTQ files were generated for each sample. The alignment of
the reads onto the UCSC reference genome (hg19) and splice site
identification were performed using Bowtie/TopHat, with map-
ping allowing up to two mismatches [25]. An average of
25.860.34 (mean 6 STD) and 24.060.42 million 26100-bp
reads per control and atorvastatin-treated sample were obtained,
respectively. The aligned reads were assembled into transcripts
using the Cufflinks software [26]. Cufflinks computes normalized
values termed FPKM (fragments per kilobase of exon per million
fragments mapped), which reflect the mRNA expression levels
[26]. The reads were mapped to a total of 23,138 Refseq genes
and 39,843 Refseq transcript splice variants. Statistical analysis of
differentially expressed genes and transcript splice variants,
differential splicing and differential promoter usage was performed
using Cuffdiff, which is integrated into Cufflinks. In the differential
splicing analysis, Cuffdiff calculates the changes in the relative
abundance of splice variants produced from a single primary
transcript sharing a common transcription start site, such as a
change in the splicing pattern. In the differential promoter usage
analysis, Cuffdiff tests for differential promoter use in genes with
two or more promoters that generate primary transcripts with
different start sites. The status code ‘‘OK’’ in Cuffdiff indicates
that there are a sufficient number of reads in a locus to make a
reliable calculation. The default false discovery rate (FDR) of
Cuffdiff is 5%. The results were visualized using the CummeR-
bund package [27] in the statistics environment R [28]. The
CummeRbund package is available from the Bioconductor
website [29]. Sequence reads have been deposited in the NCBI
BioSample database (http://www.ncbi.nlm.nih.gov/biosample)
with the following accessions: SAMN02808181, SAMN02808182,
SAMN02808183, SAMN02808184, SAMN02808185 and
SAMN02808186.
Exon Array
Total RNA (100 ng) from each sample was prepared using the
Ambion WT Expression Kit (Ambion Inc., Austin, TX, USA),
according to manufacturer’s instructions. Fragmented and labeled
sense strand DNA was hybridized to the GeneChip Human Exon
1.0 ST Array (Affymetrix, Santa Clara, CA, USA). The array
contained approximately four probes per exon and 40 probes per
gene. The arrays were washed and stained using an FS-450 fluidics
station (Affymetrix) and were scanned using a Hewlett Packard
Gene Array Scanner 3000 7G (Hewlett Packard, Palo Alto, CA,
USA). The scanned images were then analyzed using the
Affymetrix GeneChip Command Console. The CEL files were
imported into the Partek Genomics Suite software (Partek, Inc., St.
Louis, MO) for data analysis. Robust microarray analysis (RMA)
was applied for normalization. The exon array data were filtered
to include only those probe sets derived from the core meta-probe
list, representing approximately 17,000 RefSeq genes and full-
length GenBank mRNAs. The gene expression level was estimated
by averaging all of the core probe sets for that gene. Paired sample
t-tests were performed to analyze the differential gene expression
between the control and atorvastatin-treated HepG2 samples. A
Benjamini-Hochberg correction was used to correct for multiple
comparisons. A 5% FDR was considered statistically significant.
The data have been deposited in NCBI’s Gene Expression
Omnibus [30] and are accessible through the GEO Series
accession number GSE57071 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc =GSE57071).
Comparison between RNA-seq and exon array
The strength of the linear relationship between the RNA-seq
and exon array data was measured using Pearson’s correlation
coefficient on the log2 values obtained for the 17,151 genes that
were detected using both methods. A constant offset of 1 was
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added to the FPKM values to handle the log2 transformation of
zero values.
Pathway analysis of differentially expressed gene lists
Statistically significant genes were imported into Ingenuity
Pathway Analysis (www.ingenuity.com; Ingenuity Systems, Red-
wood City, CA, USA). The Core analysis was used to identify the
main biological functions and canonical pathways associated with
the differentially expressed genes.
Validation by reverse transcription quantitative PCR
(RTqPCR)
Total RNA (200 ng) was subjected to cDNA synthesis in a
20 mL reaction using the qScript cDNA Synthesis Kit (Quanta
BioSciences, Gaithersburg, MD, USA) according to the manufac-
turer’s instructions and stored at 220uC until analysis. All qPCRs
were performed on a ViiA 7 Real-Time PCR System in a standard
96-well format in a 20 mL reaction mixture containing 10 mL of
TaqMan Universal PCR Master Mix, 7 mL of RNase-free water,
1 mL of Taqman gene expression assay and 2 mL of a 1:5 dilution
of each cDNA sample (Applied Biosystems, Foster City, CA,
USA). The cycling steps were 10 min at 95uC followed by 40
cycles of 95uC for 15 s and 60uC for 1 min. The following genes
and Taqman gene expression assays (Applied Biosystems) were
selected to validate the RNA-seq results: HMGCR
(Hs01102990_m1), IL21R (Hs00222310_m1), PPIA
(Hs99999904_m1) and TBP (Hs99999910_m1). PPIA and TBP
have previously been validated in our laboratory to be suitable for
normalization in atorvastatin-treated HepG2 cells [24]. Each
sample was run in duplicate. The quantification cycle (Cq) values
were normalized according to the DDCq method for calculating
fold changes in the mRNA levels [31]: DDCq=22(DCq_treated –
DCq_non-treated)
Results
Dose-response curve
The mRNA levels of HMGCR in HepG2 cells increased in
response to increasing concentrations of atorvastatin (Figure S1).
The increases in the HMGCR mRNA levels after 24 h of
atorvastatin treatment were 1.260.06-fold (mean6S.E at the
concentration of 2.5 mM atorvastatin), 1.260.16-fold (5 mM),
1.760.19-fold (10 mM), 2.460.26-fold (20 mM) and 2.660.29-fold
(40 mM) compared to that of the untreated HepG2 cells
(1.060.21). The concentration of 10 mM atorvastatin was within
the linear range of the dose-response curve and was therefore used
in subsequent experiments.
RNA-seq
Expression level. A graph of the atorvastatin FPKM versus
control FPKM expression values is shown in Figure 1. A total
number of 12,426 genes were expressed when filtering for the test
status "OK" in the output file containing the differential
expression results. The median FPKM was 9.1 (interquartile
range IQR 3.3–23) in the control samples and 9.2 (IQR 3.4–23) in
the atorvastatin-treated samples.
Differential gene expression analysis. Cuffdiff identified
121 genes to be differentially expressed, with an expected FDR of
5%. A total of 110 genes were upregulated, and 11 genes were
downregulated by atorvastatin treatment. The differentially
expressed genes showed at least a 1.2-fold change in expression.
The statistically significant fold changes ranged from -2.4-fold to +
4.1-fold. HMGCR and LDLR expression, which can be used as
cellular markers of an in vitro statin response, were significantly
increased by 1.8-fold and 1.5-fold, respectively. The 121
differentially expressed genes were subjected to Ingenuity Pathway
Analysis. The top five biological functions (Table 1 and Table S1)
and canonical pathways (Table 2 and Table S2) associated with
these genes are shown. Lipid metabolism and the cholesterol
biosynthesis pathway were the major affected biological processes,
and this finding supports the on-target effects of the in vitro
atorvastatin treatment.
Differential expression analysis of transcript splice
variants. A total of 98 known transcript splice variants were
differentially expressed in atorvastatin-treated samples with an
FDR of 5% (Table S3). A total of 91 transcript splice variants were
upregulated, and seven transcript splice variants were downreg-
ulated. The differentially expressed transcript splice variants
showed at least a 1.2-fold change in expression. The statistically
significant fold changes ranged from -2.3-fold to +4.1-fold. Eight of
these 98 splice variants originated from the same genes, i.e., two
different transcript splice variants each of ACLY, FDPS,
HMGCS1 and LSS were significantly upregulated. The two lists
of significantly differentially expressed genes (n = 121) and splice
variants (n = 98) were then compared: 11 splice variants were not
encoded by the 121 significant genes (Table 3). A barplot of one of
these 11 genes, BCL2L11, is shown in Figure 2. By systematically
exploring the expression level of each atorvastatin responsive splice
variant, we discovered four minor splice variants encoded by the
ZNF195, SP1, DTNA and FAM189B genes. FAM189B was
significant in both the gene and the splice variant expression
analysis.
Differential promoter usage analysis. Statistical testing
for differential promoter usage after atorvastatin treatment
revealed RAP1GAP to be significant. A barplot of FPKM values
with confidence intervals for RAP1GAP splice variants is shown in
Figure S2.
Differential splicing analysis. A total of 11 genes had a
different splicing pattern after atorvastatin treatment. These were
SYCP3, ZNF195, ZNF674, MYD88, WHSC1, KIF16B,
Figure 1. Bland-Altman plot for the comparison of FPKM
expression values of the control and atorvastatin-treated
HepG2 cells. Significantly differentially expressed genes are highlight-
ed in red (n = 121).
doi:10.1371/journal.pone.0105836.g001
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ZNF92, AGER, FCHO1, SLC6A12 and AKAP9, ordered by
increasing p-values (Figure S3-13, respectively).
Exon array
Differential gene expression analysis. No genes were
found to be differentially expressed after a Benjamini-Hochberg
correction was applied to the data at a FDR of less than 5%.
RNA-seq gene expression comparison with exon array
The RNA-seq and exon array data from the same samples were
compared. The gene expression levels analyzed by RNA-seq and
exon array were in agreement (R=0.81, Figure 3). The dynamic
range of RNA-seq was larger than that of the exon array; the
FPKM fold changes varied from 24.3 to 4.1, whereas the exon
array expression value fold changes varied from 21.6 to +1.9.
RT-qPCR validation of differentially expressed genes
RNA-seq, exon array and RT-qPCR analysis confirmed the
stable expression of PPIA and TBP between treatment groups.
The fold changes of HMGCR mRNA levels were in good
agreement among the three methods: HMGCR was upregulated
1.8-fold in the RNA-seq data, 1.5-fold in the exon array data and
2.2-fold in the RT-qPCR data. IL21R was the most upregulated
gene (4.1-fold change), but its mRNA level was low (FPKM=0.74
in atorvastatin sample). In the exon array data, IL21R expression
was not altered by atorvastatin treatment (1.2-fold, p=0.157). In
the RT-qPCR data, IL21R was upregulated 7.1-fold. These
results indicate that RNA-seq is able to quantify changes in low-
abundance transcripts that were not discovered in the exon array.
Discussion
Because the expression level of a minor transcript splice variant
of HMGCR lacking exon 13 may explain variable cholesterol
response to statins, we wanted to explore statin-induced gene
Table 1. Top biological functions identified by Ingenuity Pathway Analysis affected by atorvastatin treatment.
Molecular and Cellular Functions p-value # Genes
Lipid Metabolism 3.87E-24 - 1.61E-02 65
Small Molecule Biochemistry 3.87E-24 - 1.61E-02 68
Vitamin and Mineral Metabolism 3.87E-24 -1.63E-02 36
Molecular Transport 1.25E-14 - 1.63E-02 51
Nucleic Acid Metabolism 1.41E-08 - 1.61E-02 14
Diseases and Disorders
Cardiovascular Disease 4.77E-11 - 1.72E-02 16
Metabolic Disease 4.77E-11 - 1.61E-02 36
Endocrine System Disorders 2.97E-09 - 1.61E-02 18
Neurological Disease 7.49E-08 - 1.61E-02 40
Psychological Disorders 7.49E-08 - 2.37E-07 20
Physiological System Development and Function
Digestive System Development and Function 2.93E-06 - 2.93E-06 8
Hepatic System Development and Function 2.93E-06 - 1.61E-02 9
Organ Morphology 2.93E-06 - 1.72E-02 20
Organismal Development 6.72E-05 - 1.72E-02 20
Tissue Morphology 3.85E-04 - 1.61E-02 23
The number of differentially expressed genes associated with functional categories in atorvastatin treated HegG2 cells is shown. Note that several genes are represented
in more than one category. A complete list of the biological functions and associated genes is presented in Table S1.
doi:10.1371/journal.pone.0105836.t001
Table 2. Top five canonical pathways associated with the differentially expressed genes (n = 121) in atorvastatin treated HepG2
cells identified by Ingenuity Pathway Analysis.
Top canonical Pathways p-value Ratio
Cholesterol Biosynthesis 5.46E-25 12/13(0.92)
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 5.46E-25 12/13(0.92
Cholesterol Biosynthesis III (via Desmosterol) 5.46E-25 2/13 (0.92)
Zymosterol Biosynthesis 1.89E-10 5/6 (0.83)
Mevalonate Pathway I 2.17E-10 6/12 (0.5)
Canonical pathways are ordered by p-value. The ratio shows the number of genes in the dataset divided by the number of genes in the pathway. A complete list of the
canonical pathways and associated genes is presented in Table S2.
doi:10.1371/journal.pone.0105836.t002
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Figure 2. Transcript splice variants and expression of the BCL2L11 gene. (A) The canonical splice variant with accession number NM_138621
and the alternatively spliced variant NM_006538 of BCL2L11 are shown. Sixteen additional transcript variants of BCL2L11 are annotated in the National
Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) database (not shown here). Exons are represented by blue boxes
separated by intervening sequences (introns). (B) The CummeRbund expression bar plot is shown. FPKM, fragments per kilobase of transcript per
million fragments mapped, reflects the mRNA expression level of NM_138621 and NM_006538 in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells. The HepG2 samples showed low expression levels of the other sixteen alternatively spliced variants (FPKM,1). An asterisk indicates the
statistically significant down-regulation of NM_138621 upon atorvastatin treatment after a Benjamini-Hochberg correction (5% FDR). The alternatively
spliced variant NM_006538 was slightly upregulated.
doi:10.1371/journal.pone.0105836.g002
Table 3. The 11 genes uniquely identified by differential expression analysis of transcript splice variants, but not identified by
differential gene expression analysis, are shown.
Gene ID Transcript FPKM Atv FPKM Ctr Fold Change Official full name
ZNF195 NM_001242841 3.6 1.6 -2.3 zinc finger protein 195 Splice variant 4
MGC23284 (SNAI3-AS1) NR_024402 1.1 2.2 2.1 SNAI3 antisense RNA
1 non-coding RNA
Splice variant 1
BCL2L11 NM_138621 3.9 2.0 -2.0 BCL2-like11 (apoptosis facilitator) Splice variant 1
MICA NM_000247 11.8 17.1 1.5 MHC class I polypeptide-related
sequence A
Splice variant 1
TACC2 NM_206862 2.9 4.2 1.4 transforming, acidic coiled-coil
containing protein 2
Splice variant 1
C10orf58 (FAM213A) NM_032333 42.7 51.3 1.2 family with sequence similarity
213, member A
Splice variant 1
DTNA NM_001198941 0.0 1.1 N/A dystrobrevin, alpha Splice variant 13
PLCXD2 NM_001185106 0.0 0.7 N/A phosphatidylinositol-specific
phospholipase C, X domain containing 2
Splice variant 1
ZNF419 NM_001098496 0.0 0.8 N/A zinc finger protein 419 Splice variant 7
SP1 NM_003109 1.3 0.0 N/A Sp1 transcription factor Splice variant 2
ZNF674 NM_001146291 0.5 0.0 N/A zinc finger protein 674 Splice variant 2
doi:10.1371/journal.pone.0105836.t003
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expression at the level of splice variants. RNA-seq detected that
the expression levels of 98 transcript splice variants were altered by
atorvastatin treatment. In the majority of cases, atorvastatin
changed the mRNA expression level of major splice variants.
Unfortunately, there were not sufficient reads to test for the
differential expression of the minor splice variant of HMGCR
lacking exon 13. However, we discovered four minor splice
variants that apparently changed more with atorvastatin than did
the major ones. None of these genes were previously known to be
associated with the statin response. The proteins encoded by two
of the genes, ZNF195 and SP1, are zinc finger transcription
factors that are involved in cellular processes such as cell growth,
apoptosis, differentiation and immune responses [32,33]. The
third gene, DTNA, encodes a protein that belongs to the
dystrophin family and plays a role in synapse formation and
stability, whereas the protein encoded by the fourth gene,
FAM189, potentially binds to a WW domain-containing protein
involved in apoptosis and tumor suppression [34,35]. The
significance of increased expression of these minor splice variants
in statin therapy has yet to be determined.
We could confirm that statins induce the expression of a wide
range of genes, most notably genes involved in lipid metabolism
[13]. Furthermore, by focusing on the expression levels of splice
variants, we identified 11 additional splice variants (produced from
11 different genes) that were not on the list of differentially
expressed genes. For example, the canonical BCL2L11 splice
variant, which acts as an apoptotic activator, was downregulated
in response to atorvastatin treatment (Figure 2), whereas the other
16 alternatively spliced variants of the BCL2L11 gene were not
affected or were only slightly upregulated. This finding shows that
the regulation of single splice variants does not necessarily
influence the total gene expression of a gene, suggesting that a
more detailed picture is needed when investigating changes in
gene expression levels.
RNA-seq technology has an advantage over microarray
technology in providing information at the single-base resolution.
The high resolution enables the identification of exon boundaries
and thus the ability to better distinguish between different splice
variants [36]. In our experiment, paired-end sequencing was
performed. By using paired-end reads in the analysis, the detection
of splice variants and the determination of splicing patterns are
improved because cDNA fragments are sequenced from both ends
[37]. It is, however, challenging that many alternative exons are
expressed at rather low levels. For the majority of the genes
analyzed (including BCL2L11), there were not sufficient reads in
the locus to make a reliable calculation of differential splicing and
promoter use. This may explain the minimal overlap between
significant genes in the splice variant analysis (n = 98) and the
differential splicing analysis (n = 11). The zinc finger transcription
factor gene, ZNF195, was the only gene that was significant in
both of the analyses.
Comparative studies of the array-based and RNA-seq platforms
agree that RNA-seq is more sensitive and has a greater dynamic
range than do array-based methods, with nearly no background
and little technical variation [38–41]. The exon array data
revealed that the magnitudes of expression changes were rather
low after atorvastatin treatment. After correcting for multiple
testing, there were no significantly differentially expressed genes in
the exon array data, though there were 121 significantly differently
expressed genes in the RNA-seq data. There was nevertheless a
good accordance between the exon array and RNA-seq expression
values, as previously demonstrated in other studies [41]. The
larger dynamic range in RNA-seq data compared with the exon
array allowed for the identification of the interleukin 21 receptor
(IL21R). The differential gene expression of IL21R was not
detected by exon array and has not previously been shown to be
involved in the statin response. The upregulation of IL21R
mRNA level was confirmed by RT-qPCR supporting the
reliability of our RNA-seq data. This finding also highlights the
potential of RNA-seq analysis to complement and extend
microarray measurements, as noted by other researchers
[15,41]. IL21R encodes a receptor for interleukin 21, a group of
cytokines that have immunoregulatory activity and are important
in T cells, B cells, and natural killer cell responses. Statins appear
to have anti-inflammatory properties independent of the lipid-
lowering effect, although the clinical significance of this is unclear
[42,43]. It would be interesting to investigate the clinical role of
increased IL21R expression in statin therapy.
We used theHMGCR expression levels as a marker of the statin
response and found that a concentration of 10 mM gave nearly a
half-maximal response in HepG2 cells cultured in LPDS medium.
A high concentration of statins (100 mM) may, however, be
employed when studying processes related to its toxic effects
[8,44]. For example, the number of differently expressed genes in
our study using a concentration of 10 mM atorvastatin is
substantially lower than that of another study, which used a
100 mM concentration of the drug (121 genes versus 1091 genes)
[8]. However, in that study, the authors also identified lipid
metabolism as the major biological function affected by the
atorvastatin treatment, although they did not culture the cells in
LPDS medium as we did. Their PCR results that demonstrated
increased expression of genes involved in cholesterol metabolism
(such as ACAT2, HMGCS, HMGCR, SQLE, LSS) were similar to
our results.
In vitro effects of statins appear to be largely cell type-
dependent. In epithelial cells, 10 mM atorvastatin treatments for
24 hours have been shown to induce anti-thrombotic effects due to
the increased expression of genes coding for endothelial nitric
Figure 3. RNA-seq and exon array expression values. A
comparison of RNA-seq FPKM and exon array RMA intensity values
for the 17,151 genes detected using both methods in HepG2 control
cells (R= 0.81) is shown. Significantly differentially expressed genes
identified by RNA-seq are highlighted in red.
doi:10.1371/journal.pone.0105836.g003
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oxide synthase, thrombomodulin, heat shock protein 27 and tissue
plasminogen activator [45]. In the human umbilical vein
endothelial cell line, EA.hy926, the increased expression of various
Kruppel-like transcription factors, which have tumor-suppressing
functions, and the modulation of cell cycle related genes (such as
CCNA2, CCNE2, CCNB1 and CCNB2) provides evidence for an
anti-cancer effect of atorvastatin [46]. In human peripheral blood,
an anti-inflammatory activity of atorvastatin has been detected due
to decreased mRNA levels of chemokines (CCL2, CCL7, CCL13,
CCL18, CXCL1) and cytokines (IL-6, IL-8, IL-1, PAI-1, TGF-
beta1, TGF-beta2) [9]. None of these genes were significantly
affected in our analysis of HepG2 cells.
A major limitation of the present study is the small number of
biological replicates. Only three control samples and three atorvas-
tatin-treated samples were analyzed. The results from our study
should be replicated and presented with dose-response data to confirm
the significance of the results we obtained, particularly the results from
transcripts that were present at a low abundance. To conclude, we
have identified several novel candidate genes that are affected by
atorvastatin treatment in HepG2 cells. It would be interesting to study
the biological significance of the atorvastatin-responsive splice variants
that have been uniquely identified with RNA-seq.
Supporting Information
Figure S1 Dose response curve of HMGCR gene expression.
HepG2 cells were incubated for 24 h in culture medium
containing lipoprotein deficient serum with indicated concentra-
tion of atorvastatin. HMGCR mRNA levels were determined by
RT-qPCR using Taqman gene expression assay specific for
HMGCR and two validated references genes for normalization.
The results are shown as the mean fold change compared with
mRNA levels in un-treated cells from four independent experi-
ments. Error bars indicate standard errors (6S.E), n = 4.
(PNG)
Figure S2 Differential promoter usage for RAP1GAP. A barplot
of expression values with confidence intervals for RAP1GAP is
shown. FPKM, fragments per kilobase of transcript per million
fragments mapped, reflects the mRNA expression level of
transcript splice variants in the un-treated (Ctrl) and atorvastatin
treated (Stat) HepG2 cells.
(JPEG)
Figure S3 Differential splicing of SYCP3. A barplot of
expression values with confidence intervals for SYCP3 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S4 Differential splicing of ZNF195. A barplot of
expression values with confidence intervals for ZNF195 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S5 Differential splicing of ZNF674. A barplot of
expression values with confidence intervals for ZNF674 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(JPEG)
Figure S6 Differential splicing of MYD88. A barplot of
expression values with confidence intervals for MYD88 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S7 Differential splicing of WHSC1. A barplot of
expression values with confidence intervals for WHSC1 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S8 Differential splicing of KIF16B. A barplot of
expression values with confidence intervals for KIF16B is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S9 Differential splicing of ZNF92. A barplot of
expression values with confidence intervals for ZNF92 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S10 Differential splicing of AGER. A barplot of
expression values with confidence intervals for AGER is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S11 Differential splicing of FCHO1. A barplot of
expression values with confidence intervals for FCHO1 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S12 Differential splicing of SLC6A12. A barplot of
expression values with confidence intervals for SLC6A12 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Figure S13 Differential splicing of AKAP9. A barplot of
expression values with confidence intervals for AKAP9 is shown.
FPKM, fragments per kilobase of transcript per million fragments
mapped, reflects the mRNA expression level of transcript splice
variants in the un-treated (Ctrl) and atorvastatin treated (Stat)
HepG2 cells.
(PNG)
Table S1 Biological functions and associated genes identified by
Ingenuity Pathway Analysis in atorvastatin treated HepG2 cells.
(XLS)
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Table S2 Canonical pathways and associated genes identified by
Ingenuity Pathway Analysis in atorvastatin treated HepG2 cells.
(XLS)
Table S3 A comprehensive list of the 98 differently expressed
splice variants identified by RNA-seq after atorvastatin treatment
in HepG2 cells (cut off: l1.2l fold change, 5% FDR).
(DOC)
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